#1 Clinical Trials Search in Europe

Enomimeran

Enomimeran, a novel drug candidate, is currently being investigated in clinical trials for its potential in treating advanced cancers. This article explores two ongoing studies that are evaluating the efficacy and safety of Enomimeran in combination with other therapies for non-small cell lung cancer and melanoma. These trials aim to provide new treatment options for patients who have not responded to previous therapies.

Table of Contents

What is ENOMIMERAN?

ENOMIMERAN is an innovative cancer vaccine being developed as a potential treatment for advanced stages of certain cancers. It belongs to a class of drugs known as mRNA vaccines, which use genetic material to stimulate the immune system to fight cancer cells[1]. ENOMIMERAN is also known by several other names, including RBL003.3 and “5′-capped mRNA encoding MAGE-A3”[1].

How does ENOMIMERAN work?

ENOMIMERAN works by delivering mRNA (messenger RNA) that encodes for a specific protein called MAGE-A3, which is commonly found on certain types of cancer cells. When injected into the body, this mRNA instructs cells to produce the MAGE-A3 protein. The immune system then recognizes this protein as foreign and mounts an attack against it, potentially also targeting cancer cells that naturally express MAGE-A3[1].

In clinical trials, ENOMIMERAN is being studied both alone and in combination with other cancer treatments, particularly immune checkpoint inhibitors like cemiplimab. These combinations aim to enhance the body’s immune response against cancer cells[1].

What conditions is ENOMIMERAN being studied for?

ENOMIMERAN is currently being investigated for the treatment of two main types of advanced cancers:

  • Advanced Non-Small Cell Lung Cancer (NSCLC): This is a type of lung cancer that has spread beyond the initial tumor site or to other parts of the body[1].
  • Advanced Melanoma: This refers to skin cancer that has spread to other parts of the body (stage III or IV)[2].

Current Clinical Trials

Two major clinical trials are currently underway to evaluate the effectiveness and safety of ENOMIMERAN:

  1. EMPOWERVAX Lung 1 Trial: This is a Phase 2 study comparing the combination of ENOMIMERAN (as part of the BNT116 vaccine) and cemiplimab versus cemiplimab alone in patients with advanced NSCLC[1].
  2. BNT111 Melanoma Trial: This is another Phase 2 study investigating ENOMIMERAN (as part of the BNT111 vaccine) alone or in combination with cemiplimab for patients with advanced melanoma who have not responded to previous treatments[2].

How is ENOMIMERAN administered?

ENOMIMERAN is administered as an intravenous (IV) injection. In the clinical trials, it is given in combination with other treatments, such as cemiplimab, which is administered as an IV infusion. The exact dosing schedule and amount may vary depending on the specific trial and treatment plan[1].

Potential Side Effects

As ENOMIMERAN is still in clinical trials, the full range of potential side effects is not yet known. However, common side effects associated with cancer vaccines and immunotherapies may include:

  • Fatigue
  • Fever or chills
  • Injection site reactions
  • Flu-like symptoms
  • Potential immune-related adverse events

The clinical trials are closely monitoring patients for any adverse reactions to better understand the safety profile of ENOMIMERAN[2].

Who may be eligible for ENOMIMERAN treatment?

Eligibility for ENOMIMERAN treatment in clinical trials typically includes:

  • Patients with advanced NSCLC or melanoma
  • Those who have not responded to or have progressed after previous treatments
  • Patients with specific tumor characteristics (e.g., PD-L1 expression levels for the NSCLC trial)
  • Adults aged 18 years or older
  • Adequate organ function and overall health status

Specific eligibility criteria may vary between trials, and patients should consult with their healthcare providers to determine if they might qualify for a clinical trial involving ENOMIMERAN[1].

Future Research and Potential

ENOMIMERAN represents an exciting new approach in cancer treatment, leveraging the body’s own immune system to fight cancer. As research continues, scientists hope to better understand how ENOMIMERAN works, which patients might benefit most from this treatment, and how it can be combined with other therapies for maximum effectiveness.

If the current clinical trials show promising results, ENOMIMERAN could potentially become an important new option for patients with advanced NSCLC and melanoma who have limited treatment options. Future studies may also explore its use in other types of cancers or at earlier stages of disease[2].

Aspect Details
Drug Name Enomimeran (BNT116, BNT111)
Cancer Types Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Melanoma
Trial Phases Phase 2
Combination Therapy Cemiplimab (anti-PD-1 antibody)
Administration Intravenous injection
Primary Endpoints Objective Response Rate (ORR)
Secondary Endpoints Duration of Response (DOR), Progression-Free Survival (PFS), Overall Survival (OS)
Patient Population Adults with advanced cancers who have progressed on or after prior therapies
Key Inclusion Criteria Measurable disease, adequate organ function, ECOG performance status ≤1
Key Exclusion Criteria Active brain metastases, significant autoimmune diseases, recent use of immunosuppressive medications

FAQ

  • What is Enomimeran? Enomimeran is an investigational drug that is part of a new class of cancer treatments. It is a type of mRNA (messenger RNA) that encodes for specific proteins associated with cancer cells, potentially helping the immune system to recognize and attack these cells.
  • What types of cancer is Enomimeran being tested for? Based on the provided clinical trial information, Enomimeran is being tested for advanced non-small cell lung cancer (NSCLC) and advanced melanoma (skin cancer).
  • How is Enomimeran administered? Enomimeran is administered intravenously, meaning it is given directly into the bloodstream through a vein.
  • Is Enomimeran being used alone or in combination with other drugs? In the clinical trials described, Enomimeran is being tested both alone and in combination with other drugs. For example, it is being studied in combination with cemiplimab, an immunotherapy drug.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the anti-tumor activity, safety, and tolerability of Enomimeran, either alone or in combination with other drugs. The trials aim to measure objective response rates, duration of response, progression-free survival, and overall survival in patients with advanced cancers.

Ongoing Clinical Trials on Enomimeran

  • Study on the Effects and Safety of Cemiplimab and BNT116 in Adults with Advanced Non-Small Cell Lung Cancer

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland Spain

  • Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Spain

Glossary

  • Enomimeran: An investigational drug that is a type of mRNA (messenger RNA) encoding for specific cancer-associated proteins, designed to stimulate the immune system against cancer cells.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that is the most common form of lung cancer, accounting for about 80-85% of all cases.
  • Melanoma: A serious type of skin cancer that develops in the cells (melanocytes) that produce melanin, the pigment that gives your skin its color.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
  • Intravenous (IV): Administered directly into a vein.
  • Clinical trial: A research study that prospectively assigns human participants to one or more health-related interventions to evaluate the effects on health outcomes.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-cemiplimab-and-bnt116-in-adults-with-advanced-non-small-cell-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-of-bnt111-and-cemiplimab-for-patients-with-advanced-melanoma-unresponsive-to-prior-treatments/